The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.
By studying a nationwide cohort of more than 16,600 individuals with viral hepatitis, researchers determined whether the use of lipophilic and hydrophilic statins can impact hepatocellular carcinoma...
The benefit, safety, and duration of anticoagulant treatment in patients with cirrhosis and portal vein thrombosis is contentious, so researchers sought to determine the impact the therapy has on survival...
Infection with HCV has been shown to be associated with an increased risk of cardiovascular disease events, but whether treatment with DAA agents affects this risk is currently unclear.
A new study presented during a late-breaking session at The Liver Meeting evaluated the safety and efficacy of oral seladelpar among more than 100 patients with primary biliary cholangitis.
At ACG 2018, hepatologist Mitchell Shiffman, MD, outlined current concerns and special populations in the treatment of hepatitis C virus following the emergence of DAAs.
Researchers evaluated data of more than 200 patients to see whether a thrombopoietin receptor agonist could serve as an alternative to blood transfusion in thrombocytopenia and chronic liver disease.
